- Home
- PPBT vs EVAX Comparison
PPBT vs EVAX Comparison
Compare PPBT & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- EVAX
- Stock Information
- Founded
- PPBT 2010
- EVAX 2008
- Country
- PPBT Israel
- EVAX Denmark
- Employees
- PPBT N/A
- EVAX N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PPBT Health Care
- EVAX Health Care
- Exchange
- PPBT Nasdaq
- EVAX Nasdaq
- Market Cap
- PPBT 2.1M
- EVAX 17.8M
- IPO Year
- PPBT N/A
- EVAX 2021
- Fundamental
- Price
- PPBT $0.61
- EVAX $2.93
- Analyst Decision
- PPBT Strong Buy
- EVAX Strong Buy
- Analyst Count
- PPBT 1
- EVAX 2
- Target Price
- PPBT $33.00
- EVAX $10.00
- AVG Volume (30 Days)
- PPBT 2.9M
- EVAX 68.5K
- Earning Date
- PPBT 11-14-2025
- EVAX 10-30-2025
- Dividend Yield
- PPBT N/A
- EVAX N/A
- EPS Growth
- PPBT N/A
- EVAX N/A
- EPS
- PPBT N/A
- EVAX N/A
- Revenue
- PPBT N/A
- EVAX $3,176,000.00
- Revenue This Year
- PPBT N/A
- EVAX N/A
- Revenue Next Year
- PPBT N/A
- EVAX $425.50
- P/E Ratio
- PPBT N/A
- EVAX N/A
- Revenue Growth
- PPBT N/A
- EVAX 1042.45
- 52 Week Low
- PPBT $0.53
- EVAX $1.20
- 52 Week High
- PPBT $13.95
- EVAX $16.69
- Technical
- Relative Strength Index (RSI)
- PPBT 14.86
- EVAX 51.89
- Support Level
- PPBT $0.53
- EVAX $2.81
- Resistance Level
- PPBT $2.36
- EVAX $3.04
- Average True Range (ATR)
- PPBT 0.14
- EVAX 0.21
- MACD
- PPBT -0.05
- EVAX -0.00
- Stochastic Oscillator
- PPBT 3.95
- EVAX 68.64
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.